Top news from MedWatch this week
![Photo: MedWatch](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article12791283.ece/ALTERNATES/schema-16_9/doc7eok1wt4jdl13ye5emaw.jpg)
Monday
WS Audiology brings in head of EMEA region from Coloplast
Dupixent could dominate pediatric eczema market for up to a decade, analysis finds
Pharmacosmos expects massive growth in four years
Tuesday
Genmab-partner Seagen strikes deal on Chinese rights for Tivdak
FDA advisors support approval for Ferring’s intestinal infection medicine
Ferrosan’s financials could have motivated Lundbeck and partners’ new investment
Wednesday
Biogen and Eisai to seek regulatory approval for Alzheimer’s medicine
Alzheimer’s progression slowed by drug in major trial
Investors lose faith in GN Group, send stock price plummeting
Denmark rejects Sobi’s blood disease medicine due to ”unreasonably high” price
Thursday
Novo Nordisk inks multimillion-dollar deal with Ventus Therapeutics
Russian employees at Novo Nordisk and Coloplast have not been drafted for war
Bavarian Nordic’s vaccine against smallpox and monkeypox appears to be working
Eisai and Biogen’s Alzheimer’s success leaves many questions still unanswered
Friday
Novo advances third business leg with Ventus deal, says analyst
Large block of Genmab shares up for sale in US